6.1 Collaborative Pharmacy Practice Agreements (CPPA)

6.1 Collaborative Pharmacy Practice Agreements (CPPA)

Quick Answer: Under T.C.A. § 63-10-217 and Tenn. Comp. R. & Regs. 1140-03-.17, a Collaborative Pharmacy Practice Agreement (CPPA) allows Tennessee-licensed pharmacists to initiate, adjust, monitor, and discontinue drug therapies pursuant to a written, disease-specific clinical protocol executed with an authorizing practitioner (MD, DO, or an APRN/PA operating within supervising physician-approved protocol authority). To enter into a CPPA, the pharmacist must hold an active, unencumbered Tennessee license and maintain at least $1,000,000 in professional liability insurance coverage per occurrence. Agreements must be reviewed and re-signed biennially (every 2 years), patients must give informed consent with the right to opt out at any time, prescribers must be notified within the protocol timeframe (typically 3 business days), and all records must be retained for 10 years.

---

1. Statutory Architecture & Administrative Jurisdiction

Collaborative Pharmacy Practice in Tennessee represents a statutorily defined expansion of traditional pharmacy dispensing, bridging outpatient and ambulatory clinical care through formal, delegation-based partnerships between prescribers and pharmacists. The statutory authority is codified at Tennessee Code Annotated (T.C.A.) § 63-10-217, part of the Tennessee Pharmacy Practice Act of 1996.

Administrative rules implementing this statute are promulgated jointly through the Tennessee Board of Pharmacy (Tenn. Comp. R. & Regs. 1140-03-.17) alongside corresponding healing arts licensing boards: the corresponding healing-arts boards. Rule 1140-03-.17(12) makes the cross-reference explicit: for any practitioner participating in a collaborative pharmacy practice agreement, "the Board of Pharmacy expressly adopts the guidelines, rules, and standards of practice of the Board of Medical Examiners, Board of Osteopathic Examiners, or other Tennessee Health Related Boards, as applicable." Rule 1140-03-.17(14) adds that all signatories are subject to discipline by their own licensing boards, and that each board with jurisdiction reports suspected violations to the others.

Under T.C.A. § 63-10-217, "collaborative pharmacy practice" is defined as the practice of pharmacy in which one or more pharmacists licensed in Tennessee collaborate with one or more authorizing practitioners licensed in Tennessee to provide patient care services, including drug therapy management, under the terms of a written collaborative pharmacy practice agreement and specific clinical protocols.

[!IMPORTANT] A CPPA does not confer independent prescribing authority upon a pharmacist. Rather, it represents delegated prescriptive and clinical management authority strictly tethered to the scope, clinical pathways, laboratory thresholds, and formulary restrictions set forth in the written collaborative protocol executed with the authorizing practitioner.

---

2. Authorizing Practitioners & Practitioner Scope

The statute strictly defines which healthcare professionals may serve as authorizing practitioners in a CPPA:

┌─────────────────────────────────────────────────────────────────────────────┐
│                     CPPA PRACTITIONER ELIGIBILITY MATRIX                    │
├──────────────────────────┬──────────────────────────────────────────────────┤
│ Practitioner Type        │ Legal Authority & Supervisory Prerequisites       │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Allopathic Physician     │ Full independent statutory authority to enter a  │
│ (MD)                     │ CPPA within their medical scope of practice.     │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Osteopathic Physician    │ Full independent statutory authority to enter a  │
│ (DO)                     │ CPPA within their medical scope of practice.     │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Advanced Practice        │ May enter a CPPA ONLY if delegated by their      │
│ Registered Nurse (APRN)  │ supervising collaborating physician in their     │
│                          │ written supervisory protocol under T.C.A.        │
│                          │ § 63-7-123 and within their specialty scope.     │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Physician Assistant      │ May enter a CPPA ONLY if authorized by their      │
│ (PA)                     │ supervising physician under their protocol and   │
│                          │ T.C.A. § 63-19-106 within their clinical scope.  │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Dentists, Podiatrists,   │ INELIGIBLE to enter broad chronic disease CPPAs. │
│ Optometrists, Vets       │ Limited strictly to immediate narrow specialties │
│                          │ if authorized under specific board rules.        │
└──────────────────────────┴──────────────────────────────────────────────────┘

Mid-Level Practitioner Delegated Authority

A critical point frequently tested on the Tennessee MPJE concerns APRNs and PAs. An APRN holding an active certificate of fitness or a licensed PA cannot independently authorize a pharmacist to engage in collaborative drug therapy management beyond what the mid-level practitioner's supervising physician has formally authorized. Under Tennessee Board rules, when an APRN or PA is the authorizing practitioner signing a CPPA:

1. The collaborating supervising physician must maintain direct oversight of the mid-level practitioner.
2. The scope of the CPPA cannot exceed the medical scope or formulary permissions established in the mid-level practitioner's own supervisory practice agreement with the physician.
3. The supervising physician must be identified within the CPPA documentation.

---

3. Pharmacist Eligibility & Liability Insurance Mandates

To lawfully execute and practice under a CPPA in Tennessee, a pharmacist must satisfy rigorous professional eligibility requirements codified in Tenn. Comp. R. & Regs. 1140-03-.17:

1. Active, Unencumbered License: The pharmacist must hold an active, unencumbered license to practice pharmacy issued by the Tennessee Board of Pharmacy. A pharmacist whose license is suspended, on active disciplinary probation, or subject to practice restrictions regarding clinical decision-making is legally barred from participating in a CPPA.
2. Minimum Professional Liability Insurance: The collaborating pharmacist must maintain personal professional liability insurance coverage of not less than $1,000,000 per occurrence. If the coverage is underwritten on a "claims-made" basis rather than an "occurrence" basis, the policy must include an extended reporting period endorsement ("tail coverage") of at least $1,000,000. Proof of this insurance must be maintained at the practice site and presented to Board investigators upon inspection.
3. Clinical Competence & Training: The pharmacist must possess documented clinical competence, education, or certified training appropriate for the specific disease states and drug categories governed by the agreement (e.g., specialized residency training, board certification through the Board of Pharmacy Specialties [BPS], or disease-specific certificate training for complex therapies like anticoagulation, diabetes, or oncology).

┌─────────────────────────────────────────────────────────────────────────────┐
│                      MANDATORY PHARMACIST PREREQUISITES                     │
├─────────────────────────────────────────────────────────────────────────────┤
│ 1. Current, active, unencumbered Tennessee Pharmacist License               │
│ 2. Minimum $1,000,000 professional liability insurance (per occurrence)     │
│ 3. Practice site physically located in Tennessee (or servicing TN patients) │
│ 4. Documented clinical education/training aligned with protocol disease states│
│ 5. Signed written agreement with active authorizing Tennessee prescriber    │
└─────────────────────────────────────────────────────────────────────────────┘

---

4. Mandatory Structural Components of the Written Agreement

A CPPA must be an exhaustive, written document signed and dated by all participating practitioners and pharmacists. It is legally deficient if it consists of a vague authorization for the pharmacist to "manage medications." Under Tenn. Comp. R. & Regs. 1140-03-.17, every CPPA must explicitly incorporate the following essential elements:

A. Identification of Parties

• Full legal names, professional license numbers, physical practice addresses, and emergency contact details for all authorizing practitioners and participating pharmacists.
• Explicit provisions specifying procedures for adding or removing participating pharmacists or practitioners during the agreement term.

B. Defined Scope of Disease States

• Specific, delineated disease states or medical conditions authorized for pharmacist management.
• Common authorized outpatient conditions include: Type 1 and Type 2 Diabetes Mellitus, Essential Hypertension, Hyperlipidemia / Dyslipidemia, Anticoagulation (warfarin, DOACs), Asthma and COPD, Heart Failure, Osteoporosis, and Chronic Kidney Disease.
• The agreement must explicitly delineate which stages or patient profiles within these conditions may be managed.

C. Authorized Drug Categories & Formulary Boundaries

• A detailed list or formulary of drugs, drug classes, or medicinal devices that the pharmacist is authorized to initiate, modify (adjust dosage, dosage form, or frequency), discontinue, or substitute.
• Clear dosing ranges, titration intervals, and contraindication criteria for each authorized medication class.

D. Laboratory and Diagnostic Testing

• A comprehensive list of laboratory tests, diagnostic monitoring, and physical assessments the pharmacist is authorized to order, interpret, and act upon (e.g., Hemoglobin A1c, comprehensive metabolic panel, serum creatinine/eGFR, lipid panels, PT/INR, complete blood counts, ambulatory blood pressure monitoring, spirometry).
• Established target parameters and clinical action thresholds (e.g., target INR ranges for warfarin; target eGFR cutoffs triggering drug dose reductions or discontinuation).

E. Clinical Practice Protocols & Clinical Decision Pathways

• Evidence-based, nationally recognized clinical practice guidelines or specific institutional treatment algorithms incorporated by reference.
• Step-by-step clinical algorithms dictating when a medication may be initiated, titrated upward, stepped down, or switched.

F. Emergency Escalation Protocols

• Mandatory procedures for addressing acute medical emergencies, life-threatening clinical decompensation, severe adverse drug events, or severe allergic reactions (e.g., severe hypoglycemia <54 mg/dL, hypertensive crisis >180/120 mmHg, acute supratherapeutic INR >5.0 with bleeding, or anaphylaxis).
• Specific contact channels and direct referral protocols for emergency medical care.

G. Communication, Documentation & Notification Timelines

• The written agreement must specify the mechanism, system, and explicit timeframe for notifying the authorizing practitioner of any clinical action taken by the pharmacist.
• Standard Notification Benchmark: Unless a shorter interval is specified in the agreement, the pharmacist must document the patient encounter and transmit a summary of all drug therapy modifications and laboratory findings to the authorizing practitioner within three (3) business days (or 72 hours) of the encounter.
• The documentation must be recorded in an shared electronic health record (EHR) or transmitted via secure electronic facsimile/portal.

---

5. Biennial Review, Modification & Termination Requirements

To ensure that clinical care protocols reflect current medical science and drug safety evidence, Tennessee law enforces strict review intervals:

┌─────────────────────────────────────────────────────────────────────────────┐
│                     CPPA OPERATIONAL & REGULATORY LIFECYCLE                 │
├──────────────────────────┬──────────────────────────────────────────────────┤
│ Regulatory Action        │ Statutory Mandate & Administrative Parameter      │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Mandatory Review Cycle   │ Biennial (Every 2 Years) from effective date.    │
│                          │ All parties must review, update, and re-sign.     │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Immediate Revision       │ Required when standards of care change, drug     │
│                          │ black-box warnings are issued, or parties change. │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Termination Authority    │ Any party (pharmacist or prescriber) may cancel   │
│                          │ the agreement at any time upon written notice.   │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ On-Site Availability     │ Original or electronic copy must be readily      │
│                          │ accessible at every participating practice site.  │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Board Inspection Access  │ Must be produced immediately upon request by      │
│                          │ Board of Pharmacy or Medical Board investigators.│
└──────────────────────────┴──────────────────────────────────────────────────┘

If the two-year renewal deadline lapses without written re-execution, the CPPA becomes legally void, and any continued initiation or modification of drug therapies by the pharmacist constitutes the unlawful practice of medicine without a license under T.C.A. Title 63, Chapter 6.

---

6. Patient Rights, Informed Consent & Freedom of Choice

A cornerstone of Tennessee CPPA jurisprudence is the protection of patient autonomy:

1. Informed Consent & Written Disclosure: Prior to initiating collaborative drug therapy management, the patient (or the patient's legal guardian) must be fully informed that a collaborative pharmacy practice agreement is in place and that a licensed pharmacist will be managing their medication regimen in collaboration with their physician.
2. Absolute Right to Opt Out: The patient must be provided with the explicit opportunity to decline or withdraw from the collaborative arrangement at any time without compromising their medical care or access to their physician.
3. Unrestricted Freedom of Choice of Pharmacy: Under T.C.A. § 63-10-217(f), no CPPA may infringe upon the patient's freedom to choose where their prescription medications are dispensed. An authorizing physician or collaborating pharmacist cannot compel, coerce, or automatically steer a patient to fill prescriptions at the pharmacist's own retail, institutional, or specialty pharmacy practice site. Steering or restricting dispensing choice is an actionable violation of Tennessee antitrust and pharmacy trade rules.

---

7. Record Retention & Inspection Compliance

Under Tennessee Board of Pharmacy rules, recordkeeping for collaborative practice is more stringent than ordinary prescription record retention:

• 10-Year Document Retention: Copies of all signed collaborative pharmacy practice agreements, including all historical versions, protocol amendments, patient-specific authorizations, clinical encounter documentation, laboratory results, and prescriber notification logs, must be retained for a minimum of ten (10) years from the date of the last patient encounter or agreement termination.
• Storage Format: Records may be maintained in hard-copy or validated electronic document management systems, provided they are securely backed up and capable of being retrieved and printed within 48 hours upon request.

---

8. Practical Exam Scenarios

Scenario 1: APRN Authority Without Physician Delegation

Case: Dr. Adams, a community clinical pharmacist, is approached by Nurse Practitioner Roberts, an APRN operating a rural primary care clinic under a supervisory protocol with Dr. Vance. Roberts wishes to sign a CPPA with Dr. Adams allowing Adams to initiate insulin and GLP-1 receptor agonists for diabetic patients. Roberts signs the CPPA independently, noting that Dr. Vance is out of state on sabbatical. Legal Analysis: Under T.C.A. § 63-10-217 and Tenn. Comp. R. & Regs. 1140-03-.17, an APRN may only enter into a CPPA if the collaborating supervising physician has explicitly delegated that authority in the APRN's written supervisory protocol. Because Dr. Vance has not authorized the arrangement or approved the diabetes protocol, the CPPA is legally invalid. Dr. Adams cannot initiate or titrate therapies under this agreement.

Scenario 2: Liability Insurance Audit

Case: During a routine Board of Pharmacy inspection, an investigator reviews the CPPA records of an ambulatory care pharmacist. The pharmacist produces an active CPPA covering anticoagulation management, but their professional liability insurance certificate shows personal coverage of $500,000 per occurrence and $1,000,000 aggregate. Legal Analysis: Tenn. Comp. R. & Regs. 1140-03-.17 explicitly requires collaborating pharmacists to maintain professional liability insurance coverage of not less than $1,000,000 per occurrence. Coverage of $500,000 per occurrence violates Tennessee administrative rules. The pharmacist is subject to immediate suspension from collaborative practice, formal disciplinary action, and civil monetary penalties under Rule 1140-08.

Scenario 3: Lapsed Biennial Review

Case: A pharmacist and a family physician executed a CPPA for hypertension management on March 15, 2024. On May 1, 2026, the pharmacist adjusts a patient's lisinopril dosage from 20 mg to 40 mg daily and orders a basic metabolic panel. The agreement has not been re-signed or reviewed since March 2024. Legal Analysis: CPPAs in Tennessee must be reviewed and re-executed at least every two (2) years. The agreement expired on March 15, 2026. Because more than two years have elapsed without biennial re-signing, the agreement is void. The pharmacist's unilateral dosage increase on May 1, 2026 constitutes unauthorized prescribing and the unlawful practice of medicine.